Position in AVLN
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$1,975,200
New position
Shares Held
60,000
first reported quarter
Ownership
0.135%
of shares outstanding
% of Portfolio
0.32%
of 13F equity value
Holder Rank
#48
of 92 holders
Holding Since
Jun 2026
1 quarter on record
Voting authority
Sole 100%
Shared 0%
None 0%
Position in Biotechnology
Healthcare · as of Jun 30, 2026Avidity Partners Management LP holds $524,784,316 across 27 Biotechnology names. AVLN ranks #17 (0.4% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | DNTH |
Dianthus Therapeutics, Inc. /DE/
|
2,104,184 | $205,115,856 | |
| 2 | CGON |
CG Oncology, Inc.
|
1,398,948 | $99,395,255 | |
| 3 | ORKA |
Oruka Therapeutics, Inc.
|
760,424 | $72,369,552 | |
| 4 | JBIO |
Jade Biosciences, Inc.
|
1,700,708 | $37,789,731 | |
| 5 | ELVN |
Enliven Therapeutics, Inc.
|
550,000 | $27,912,500 | |
| 6 | AKTS |
Aktis Oncology, Inc.
|
484,200 | $15,605,766 | |
| 7 | PVLA |
Palvella Therapeutics, Inc.
|
70,000 | $10,697,400 | |
| 8 | IMUX |
Immunic, Inc.
|
669,941 | $10,296,993 |
All Filings in AVLN
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $1,975,200 | 60,000 | Shares | Sole | 2026-08-14 | |
| No filing history on record for this holder in this stock. | ||||||